Pathogenetic Basis of Aortopathy and Aortic Valve Disease
Key facts
- Who runs it
- Yale University
- Where
- Atlanta and Indianapolis, United StatesSee the 2 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 3,000 people, planned
- Started
- 10 Dec 2015
- Expected to end
- 31 Dec 2030
- Type of study
- Observational, 6 groups
- Record updated
- 13 February 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (3)Hide the full registry criteria
Who can take part
- Open to external enrollment:; Subjects with a genetic diagnosis of Marfan Syndrome (MDS), Loeys-Dietz Syndrome (LDS), or Vascular Ehlers-Danlos Syndrome (EDS); (Positive genetic testing or a previous cardiac study required to be eligible); Family members of eligible subjects (Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time)
- Closed to external enrollment:; Subjects with aortic disease including TAA* or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography); Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease); Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)
Who cannot take part
- Inability or unwillingness to provide consent (assent when indicated)
Where in United States
- Childrens Healthcare of AtlantaAtlanta, United States
- IU School of MedicineIndianapolis, United States
About the trial
What the trial wants to find out
The main purpose of this study is to define the complex genetic and pathogenic basis of thoracic aortic aneurysm (TAA) and other forms of aortopathy and/or aortic valve disease by identifying novel disease-causing genes and by identifying important genetic modifiers for aortic and aortic valve disease severity.
The 6 groups in the trial
- Aortopathy- Closed to external enrollment
Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography)
- Syndromic- Open to external enrollment
Subjects with a genetic diagnosis of Marfan Syndrome (MFS), Loeys-Dietz Syndrome (LDS), Vascular Ehlers-Danlos Syndrome (EDS) •positive genetic testing and/or a previous cardiac study required to be eligible
- Aortopathy with Positive Genetic Results- Open to Enrollment
Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography) who also have positive genetic testing results related to aortopathy.
- Aortic Valve Disease- Closed to enrollment
Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease)
- Family Members- Open to external enrollment
Family members of eligible subjects •Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time
- Controls- Closed to external enrollment
Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 13 February 2026